肿瘤微环境在肿瘤耐药中的作用

doi:10.3760/cma.j.cn371439-20210517-00107

摘要/Abstract

摘要：

肿瘤微环境(TME)与肿瘤耐药密切相关。TME可分为细胞成分和非细胞成分,细胞成分包括肿瘤相关巨噬细胞、肿瘤相关成纤维细胞、间质干细胞等,可通过招募和分泌多种保护性细胞因子增强肿瘤抗药性;非细胞成分如细胞外基质、缺氧和酸化等,可通过构建物理屏障、影响肿瘤细胞生长代谢等介导耐药。研究TME介导肿瘤耐药的机制,重塑TME,可为抗肿瘤治疗提供新的策略。

关键词: 肿瘤微环境, 抗药性, 间质细胞, 非细胞成分

Abstract:

Tumor microenvironments (TMEs) are closely related to tumor resistance. TMEs are divided into cellular components and acellular components. The cellular components include tumor-associated macrophages, tumor-associated fibroblasts, mesenchymal stem cells, etc., which can enhance tumor resistance through recruitment and secretion of a variety of protective cytokines; acellular components such as extracellular matrix, hypoxia and acidification, etc., can mediate drug resistance by constructing physical barriers, affecting tumor cell growth and metabolism. Studying the mechanisms of TME-mediated drug resistance and reshaping TMEs can provide new strategies for anti-tumor therapy.

Key words: Tumor microenvironment, Drug resistance, Stromal cells, Acellular component

傅维达, 陈梦娇, 郭贵龙, 郑书荣. 肿瘤微环境在肿瘤耐药中的作用[J]. 国际肿瘤学杂志, 2021, 48(9): 553-556.

Fu Weida, Chen Mengjiao, Guo Guilong, Zheng Shurong. Role of tumor microenvironment in tumor drug resistance[J]. Journal of International Oncology, 2021, 48(9): 553-556.

参考文献 35

[1]	Gordon S, Plüddemann A. Tissue macrophages: heterogeneity and functions[J]. BMC Biol, 2017, 15(1):53-70. DOI: 10.1186/s12915-017-0392-4. doi: 10.1186/s12915-017-0392-4
[2]	Almatroodi SA, McDonald CF, Darby IA, et al. Characterization of M1/M2 tumour-associated macrophages (TAMs) and Th1/Th2 cytokine profiles in patients with NSCLC[J]. Cancer Microenviron, 2016, 9(1):1-11. DOI: 10.1007/s12307-015-0174-x. doi: 10.1007/s12307-015-0174-x
[3]	Li X, Yao W, Yuan Y, et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma[J]. Gut, 2017, 66(1):157-167. DOI: 10.1136/gutjnl-2015-310514. doi: 10.1136/gutjnl-2015-310514
[4]	Deshmukh SK, Srivastava SK, Poosarla T, et al. Inflammation, immunosuppressive microenvironment and breast cancer: opportunities for cancer prevention and therapy[J]. Ann Transl Med, 2019, 7(20):593. DOI: 10.21037/atm.2019.09.68. doi: 10.21037/atm.2019.09.68 pmid: 31807574
[5]	Yin Y, Yao S, Hu Y, et al. The immune-microenvironment confers chemoresistance of colorectal cancer through macrophage-derived IL6[J]. Clin Cancer Res, 2017, 23(23):7375-7387. DOI: 10.1158/1078-0432.CCR-17-1283. doi: 10.1158/1078-0432.CCR-17-1283
[6]	Nakasone ES, Askautrud HA, Kees T, et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance[J]. Cancer Cell, 2012, 21(4):488-503. DOI: 10.1016/j.ccr.2012.02.017. doi: 10.1016/j.ccr.2012.02.017
[7]	Goswami KK, Sarkar M, Ghosh S, et al. Neem leaf glycoprotein regulates function of tumor associated M2 macrophages in hypoxic tumor core: critical role of IL-10/STAT3 signaling[J]. Mol Immunol, 2016, 80:1-10. DOI: 10.1016/j.molimm.2016.10.008. doi: S0161-5890(16)30214-0 pmid: 27776244
[8]	Rajabpour A, Afgar A, Mahmoodzadeh H, et al. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells[J]. Cancer Chemother Pharmacol, 2017, 80(4):765-775. DOI: 10.1007/s00280-017-3418-2. doi: 10.1007/s00280-017-3418-2
[9]	Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer[J]. Cancer Cell, 2018, 33(3):463-479. e10. DOI: 10.1016/j.ccell.2018.01.011. doi: S1535-6108(18)30011-4 pmid: 29455927
[10]	DuFort CC, DelGiorno KE, Hingorani SR, et al. Mounting pressure in the microenvironment: fluids, solids, and cells in pancreatic ductal adenocarcinoma[J]. Gastroenterology, 2016, 150(7):1545-1557. e2. DOI: 10.1053/j.gastro.2016.03.040. doi: 10.1053/j.gastro.2016.03.040
[11]	Qiao Y, Zhang C, Li A, et al. IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma[J]. Oncogene, 2018, 37(7):873-883. DOI: 10.1038/onc.2017.387. doi: 10.1038/onc.2017.387 pmid: 29059160
[12]	Zhang H, Xie C, Yue J, et al. Cancer-associated fibroblasts mediated chemoresistance by a FOXO1/TGFβ1 signaling loop in esopha-geal squamous cell carcinoma[J]. Mol Carcinog, 2017, 56(3):1150-1163. DOI: 10.1002/mc.22581. doi: 10.1002/mc.22581
[13]	Ireland L, Santos A, Ahmed MS, et al. Chemoresistance in pancreatic cancer is driven by stroma-derived Insulin-Like growth factors[J]. Cancer Res, 2016, 76(23):6851-6863. DOI: 10.1158/0008-5472.CAN-16-1201. doi: 10.1158/0008-5472.CAN-16-1201 pmid: 27742686
[14]	Zheng G, Huang R, Qiu G, et al. Mesenchymal stromal cell-derived extracellular vesicles: regenerative and immunomodulatory effects and potential applications in sepsis[J]. Cell Tissue Res, 2018, 374(1):1-15. DOI: 10.1007/s00441-018-2871-5. doi: 10.1007/s00441-018-2871-5
[15]	Shi Y, Du L, Lin L, et al. Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets[J]. Nat Rev Drug Discov, 2017, 16(1):35-52. DOI: 10.1038/nrd.2016.193. doi: 10.1038/nrd.2016.193
[16]	Chen CC, He BC, Chen YL, et al. HIC1 and RassF1A methylation attenuates tubulin expression and cell stiffness in cancer[J]. Int J Mol Sci, 2018, 19(10):2884. DOI: 10.3390/ijms19102884. doi: 10.3390/ijms19102884
[17]	Huang TX, Guan XY, Fu L. Therapeutic targeting of the crosstalk between cancer-associated fibroblasts and cancer stem cells[J]. Am J Cancer Res, 2019, 9(9):1889-1904.
[18]	He W, Liang B, Wang C, et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer[J]. Oncogene, 2019, 38(23):4637-4654. DOI: 10.1038/s41388-019-0747-0. doi: 10.1038/s41388-019-0747-0
[19]	Yeldag G, Rice A, Del Río Hernández A. Chemoresistance and the self-maintaining tumor microenvironment[J]. Cancers (Basel), 2018, 10(12):471. DOI: 10.3390/cancers10120471. doi: 10.3390/cancers10120471
[20]	Zheng HC. The molecular mechanisms of chemoresistance in cancers[J]. Oncotarget, 2017, 8(35):59950-59964. DOI: 10.18632/oncotarget.19048. doi: 10.18632/oncotarget.19048
[21]	Januchowski R, Šwierczewska M, Sterzyńska K, et al. Increased expression of several collagen genes is associated with drug resistance in ovarian cancer cell lines[J]. J Cancer, 2016, 7(10):1295-1310. DOI: 10.7150/jca.15371. doi: 10.7150/jca.15371 pmid: 27390605
[22]	Wu YH, Huang YF, Chen CC, et al. Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression[J]. Cell Death Dis, 2019, 10(4):322. DOI: 10.1038/s41419-019-1555-8. doi: 10.1038/s41419-019-1555-8
[23]	Stowers RS, Allen SC, Sanchez K, et al. Extracellular matrix stiffening induces a malignant phenotypic transition in breast epithelial cells[J]. Cell Mol Bioeng, 2016, 10(1):114-123. DOI: 10.1007/s12195-016-0468-1. doi: 10.1007/s12195-016-0468-1
[24]	Weniger M, Honselmann KC, Liss AS. The extracellular matrix and pancreatic cancer: a complex relationship[J]. Cancers (Basel), 2018, 10(9):316. DOI: 10.3390/cancers10090316. doi: 10.3390/cancers10090316
[25]	Senthebane DA, Rowe A, Thomford NE, et al. The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer[J]. Int J Mol Sci, 2017, 18(7):1586. DOI: 10.3390/ijms18071586. doi: 10.3390/ijms18071586
[26]	Govaere O, Wouters J, Petz M, et al. Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche[J]. J Hepatol, 2016, 64(3):609-617. DOI: 10.1016/j.jhep.2015.11.011. doi: 10.1016/j.jhep.2015.11.011
[27]	Fukazawa S, Shinto E, Tsuda H, et al. Laminin β3 expression as a prognostic factor and a predictive marker of chemoresistance in colo-rectal cancer[J]. Jpn J Clin Oncol, 2015, 45(6):533-540. DOI: 10.1093/jjco/hyv037. doi: 10.1093/jjco/hyv037 pmid: 25770060
[28]	Mohammed MEA, Elhassan NM. Cytoskeletal and extracellular matrix proteins as markers for metastatic triple negative breast cancer[J]. J Int Med Res, 2019, 47(11):5767-5776. DOI: 10.1177/0300060519877079. doi: 10.1177/0300060519877079 pmid: 31601144
[29]	Liang C, Shi S, Meng Q, et al. Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going[J]. Exp Mol Med, 2017, 49(12):e406. DOI: 10.1038/emm.2017.255. doi: 10.1038/emm.2017.255
[30]	肖俊娟, 李岩, 梁婧. 乏氧微环境与肿瘤免疫应答[J]. 国际肿瘤学杂志, 2017, 44(1):31-33. DOI: 10.3760/cma.j.issn.1673-422X.2017.01.008. doi: 10.3760/cma.j.issn.1673-422X.2017.01.008
[31]	Schito L, Semenza GL. Hypoxia-inducible factors: master regulators of cancer progression[J]. Trends Cancer, 2016, 2(12):758-770. DOI: 10.1016/j.trecan.2016.10.016. doi: S2405-8033(16)30159-5 pmid: 28741521
[32]	Beklen H, Gulfidan G, Arga KY, et al. Drug repositioning for P-glycoprotein mediated co-expression networks in colorectal cancer[J]. Front Oncol, 2020, 10:1273. DOI: 10.3389/fonc.2020.01273. doi: 10.3389/fonc.2020.01273 pmid: 32903699
[33]	Manoochehri Khoshinani H, Afshar S, Najafi R. Hypoxia: a double-edged sword in cancer therapy[J]. Cancer Invest, 2016, 34(10):536-545. DOI: 10.1080/07357907.2016.1245317. doi: 10.1080/07357907.2016.1245317 pmid: 27824512
[34]	Yeo CD, Kang N, Choi SY, et al. The role of hypoxia on the acquisition of epithelial-mesenchymal transition and cancer stemness: a possible link to epigenetic regulation[J]. Korean J Intern Med, 2017, 32(4):589-599. DOI: 10.3904/kjim.2016.302. doi: 10.3904/kjim.2016.302
[35]	Tao J, Yang G, Zhou W, et al. Targeting hypoxic tumor microenvironment in pancreatic cancer[J]. J Hematol Oncol, 2021, 14(1):14. DOI: 10.1186/s13045-020-01030-w. doi: 10.1186/s13045-020-01030-w